The Michigan Daily2hOpinion
Why US health care costs stay high: Subsidies, profits and elections
The cost of healthcare in the U.S. remains outrageously high, despite massive government subsidies. The system is designed to ...
Managed Healthcare Executive6h
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
devdiscourse7h
Global Health Issues Develop Amidst Breakthroughs and Concerns
Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...
The Score: Tesla, Alphabet, JPMorgan Chase and More Stocks That Defined the Week
Both JPMorgan Chase and Wells Fargo on Friday posted quarterly profits that fell from a year earlier, but by less than what ...
MedPage Today7h
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
Medscape7h
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
FiercePharma8h
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
hemophilianewstoday8h
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
Managed Healthcare Executive9h
FDA Approves Itovebi for Metastatic Breast Cancer
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...
The American Journal of Managed Care10h
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...